Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
Zacks' 7 Best Stocks
for May, 2013
FREE Report for Zacks.com
Visitors Only
Visitors Only
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
- Latest News
- Most Popular
- What is the Stock Market's Achilles Heel?
- 3 Dividend Stocks at Reasonable Prices
- RTI: Are You Doing the Elon Musk Trade?
- Buy These ETFs to Profit from "Sector Rotation"
- Oil & Gas Industry Stock Outlook - May 2013
- Uncharted Territory
- 4 Ways to Short Oil with ETFs
- Options Strategies & the Zacks Rank
- This Week's Growth & Income Stocks
- AWS 5/17: The Fed: The Only Game in Town
- PFP 5/17: The ONLY Investment Story
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/17/2013
| Company Name | Symbol | %Change |
|---|---|---|
| VIASAT INC | VSAT | 19.35% |
| OLD SECOND B | OSBC | 5.76% |
| GAMCO INVEST | GBL | 4.61% |
| CORNING INC | GLW | 4.47% |
| SYNCHRONOSS | SNCR | 4.23% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
ViroPharma Inc. ( VPHM - Snapshot Report ) and Halozyme Therapeutics’ ( HALO - Snapshot Report ) drug Cinryze moved a step ahead with the two partners announcing positive top-line data from a mid-stage trial on the drug. The phase II study was designed to evaluate the safety, and pharmacokinetics and pharmacodynamics of the subcutaneous formulation of Cinryze in combination with Halozyme's Enhanze technology, in patients suffering from hereditary angioedema (HAE).
We note that Cinryze in the intravenous form is currently marketed worldwide as a treatment for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.
The Enhanze technology is a proprietary drug-delivery platform, using Halozyme's recombinant human hyaluronidase enzyme (rHuPH20). This proprietary rHuPH20 enzyme facilitates the absorption and dispersion of drugs or fluids that are injected under the skin.
The study was conducted in HAE patients who were a part of a phase II trial evaluating the subcutaneous formulation of Cinryze when dosed alone. The data demonstrated that the addition of rHuPH20 led to higher maximum levels and greater systemic exposure of functional and antigenic C1 inhibitor (C1 INH) for both doses of Cinryze (1000 and 2000 units), compared to subcutaneous administration of Cinryze. Moreover, the combination of Cinryze with rHuPH20 resulted in mean functional C1 INH levels that protect against HAE attacks.
Our View
We currently have a Neutral recommendation on ViroPharma. The stock carries a Zacks #3 Rank (Hold rating) in the short-run. We believe that the use of the subcutaneous formulation of Cinryze in combination with Halozyme's Enhanze technology could improve flexibility and convenience of dosing among patients suffering from HAE, as compared to the subcutaneous delivery of Cinryze without rHuPH20.
Read the full Snapshot Report on VPHM
Read the full Snapshot Report on HALO